Cardiome Pharma Corp. (NASDAQ: CRME) is an integrated, commercial, specialty pharmaceutical company dedicated to the development and commercialization of new therapies that will improve the health and quality of life of patients. The company strives to find innovative medicines that provide value to patients, physicians and healthcare systems. It has two marketed products approved in Europe and other territories: Brinavess™ (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. For more information, visit the company’s website at www.cardiome.com.